The Blazeck Lab tackles challenges at the interface of immunology, engineering, and metabolism to improve human health. We utilize our expertise in cellular and protein engineering to control biological function and to develop novel therapies to fight disease.

Synthetic Immune Systems

Our immune system uses very complex processes to make exquisitely specific receptors that recognize disease causing agents, and much of our ability to fight diseases is contingent upon the development of a diverse repertoire of immune receptors. Many questions remain unanswered about these immune receptors. For instance, at a population level, can we characterize the millions of receptors each person makes? And then further determine which of these millions of receptors is most important towards recognizing and targeting a pathogen? And can we control the generation of immune receptors to have desired properties? We are striving to answer these questions by harnessing our immune system’s power in a synthetic setting to improve understanding and treatment options for numerous diseases, while developing applications for vaccine design, personalized medicine, and enzyme engineering.

Engineering Cellular Therapies

Immunotherapies are treatments designed to modulate the immune response that have shown astounding clinical potential, yet there are no current treatments with guaranteed success. We are working to engineer cellular systems with controllable, enhanced, and non-native functions that improve their impact and capability. By developing high throughput technologies to interrogate immune function, we hope to translate our findings into improvements in the next generation of cellular therapeutics. 

Developing Proteins that Fight Cancer and Control Metabolism

It is widely accepted that cancer cells have a significantly altered genomic and metabolic makeup relative to normal cells, but how can we best target these differences? By combining our expertise in metabolism and therapeutic protein engineering, are working to engineer proteins to directly target and fight cancer. For instance, certain enzymes can control the metabolic environment around tumors to inhibit their growth or to stimulate a native anti-cancer immune response. We utilize directed evolution approaches to optimize protein function and efficacy.

Saad Bhamla studies biomechanics across species to engineer knowledge and tools that inspire curiosity.

Saad Bhamla is an assistant professor of biomolecular engineering at Georgia Tech. A self-proclaimed "tinkerer," his lab is a trove of discoveries and inventions that span biology, physics and engineering. His current projects include studying the hydrodynamics of insect urine, worm blob locomotion and ultra-low-cost devices for global health. His work has appeared in the New York Times, the Economist, CNN, Wired, NPR, the Wall Street Journal and more.

Saad is a prolific inventor and his most notable inventions includes a 20-cent paper centrifuge, a 23-cent electroporator, and the 96-cent hearing aid. Saad's work is recognised by numerous awards including a NIH R35 Outstanding Investigator Award, NSF CAREER Award, CTL/BP Junior Faculty Teaching Excellence Award, and INDEX: Design to Improve Life Award. Saad is also a National Geographic Explorer and a TED speaker. Newsweek recognized Saad as 1 of 10 Innovators disrupting healthcare.

Saad is a co-founder of Piezo Therapeutics.

Outside of the lab, Saad loves to go hiking with his partner and two dogs (Ollie and Bella).

Alex Abramson is an assistant professor in the School of Chemical and Biomolecular Engineering at Georgia Tech. His research, which focuses on drug delivery and bioelectronic therapeutics, has been featured in news outlets such as The New York Times, NPR, and Wired. Abramson has received several recognitions for scientific innovation, including being named a member of the Forbes 30 Under 30 Science List and the MIT Technology Review Innovators Under 35 List. He is passionate about translating scientific endeavors from bench to bedside. Large pharmaceutical companies have exclusively licensed a portfolio of his patents to bring into clinical trials, and Abramson serves as a scientific advisor overseeing their commercialization. In addition to his scientific endeavors, Abramson plays an active role in his community by leading diversity and inclusion efforts on campus and volunteering as a STEM tutor to local students.

Abramson received a B.S. in chemical and biomolecular engineering from Johns Hopkins University and a Ph.D. in chemical engineering from MIT as an NSF Graduate Research Fellow under the direction of Professors Robert Langer and Giovanni Traverso. He conducted postdoctoral work at Stanford University as an NIH fellow with Professors Zhenan Bao and the late Sanjiv S. Gambhir.

The Abramson Lab develops ingestible, implantable, and wearable robotic therapeutic devices that solve key healthcare problems and provide measurable therapeutic outcomes. Our translationally focused research spans a multitude of areas, including (1) drug delivery devices for optimal drug adherence, (2) soft materials for bioelectronic sensors and therapeutics, and (3) preclinical drug screening technologies.